Amanote Research
Register
Sign In
P3.04-05 Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.1712
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
Z. Dong
Publisher
Elsevier BV
Related search
Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice
Cancer cytopathology
Cancer Research
Oncology
MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
Prognostic Impact of CD8 and Programmed Death-Ligand 1 Expression in Patients With Resectable Non-Small Cell Lung Cancer
British Journal of Cancer
Cancer Research
Oncology
P3.09-07 Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics With Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Elevated Serum Soluble Programmed Cell Death Ligand 1 Concentration as a Potential Marker for Poor Prognosis in Small Cell Lung Cancer Patients With Chemotherapy
Respiratory Research
Pulmonary
Respiratory Medicine
Consistency Analysis of Programmed Death-Ligand 1 Expression Between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study
Journal of Cancer
Oncology
Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?
Cancer cytopathology
Cancer Research
Oncology
Quantitative and Pathologist-Read Comparison of the Heterogeneity of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer
Modern Pathology
Forensic Medicine
Pathology
Reply to Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?
Cancer cytopathology
Cancer Research
Oncology
